NR1H4 and metabolic dysfunction-associated steatotic liver disease: Furthermore, FXR induces β-oxidation by activating peroxisome proliferator-activated receptor-α (PPARα) and facilitates the clearance of VLDL in plasma, ultimately improving metabolic dysfunction in MASLD [144,145,146].